GSK inks deal with UNICEF to provide 18M malaria vaccines

With a $170 million deal, UNICEF will acquire 18 million malaria vaccines from GSK, a global pharmaceutical company based in London.

Advertisement

GSK is the only drugmaker with an approved malaria vaccine, called Mosquirix. Since its approval, Mosquirix was deployed in 2019 to three African countries in a primary phase with plans to expand the vaccine’s access to more sub-Saharan countries. 

The UNICEF Aug. 16 deal, which covers supply for the next three years, has the potential to save thousands of lives every year, according to the humanitarian organization. In 2020, a child in Africa died at a rate of every minute from malaria, according to UNICEF.

“This vaccine rollout gives a clear message to malaria vaccine developers to continue their work because malaria vaccines are needed and wanted,” Etleva Kadilli, the director of UNICEF’s supply division, said in a news release. “We hope this is just the beginning.”

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.